
PrEP - pre-exposure prophylaxis


ICAP Grand Rounds Webinar — Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls

Landmark Studies Supported by ICAP Contribute to FDA Approval of Injection for HIV Prevention
For the first time, the U.S. Food and Drug Administration (FDA) has approved a long-acting injectable agent for the prevention of HIV, an alternative to daily pills for HIV prevention and an important step forward in the quest for global HIV epidemic control. ICAP at...
ICAP in Tanzania Celebrates the Lifesaving “Reach” of its Innovative FIKIA Project
From 2016 to 2021, a project designed and supported by ICAP at Columbia University delivered critical HIV health services to key and vulnerable populations in Tanzania. Known as FIKIA – “to reach” in Kiswahili – the project brought HIV testing, prevention, and care to...